ClinicalTrials.gg
RecruitingNCT06046495Updated Apr 23, 2025

A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer

A Phase 1 interventional study of PLB1004 in Non-Small Cell Lung Cancer, sponsored by Avistone Biotechnology Co., Ltd.. Recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-23.

Sponsored by Avistone Biotechnology Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
81
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing andamertinib in Carcinoma, Non-Small-Cell Lung — 9 open to participants now, 10 under way, 2 of them phase 3. andamertinib · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
9th of 11
81 · median 120
Started
2024
with 1 other
Phase 1
2 of 11
1 open now
Registered
3rd of 11
by date
Lead sponsor
8 of 11
Avistone Biotechnology Co., Ltd.

Among the 11 studies testing andamertinib in Carcinoma, Non-Small-Cell Lung, this one is the 9th largest by planned enrollment, is one of 2 that started in 2024, is one of 2 in phase 1, and was the 3rd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

9 of the 11 studies testing andamertinib in Carcinoma, Non-Small-Cell Lung are open now, in 2 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

About andamertinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing andamertinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a Phase I, multicenter, open-label, dose escalation and dose expansion study to assess the safety and pharmacokinetic profile of PLB1004, a mono-anilino-pyrimidine compound, given alone in NSCLC patients with EGFR exon 20 insertion mutations,uncommon mutations, classical mutations (Ex19del and L858R), and drug-resistant mutation (T790M). Patients will be enrolled and dosed according to the most current protocol. This study is made of two Parts. Part 1 includes a dose escalation into 7 cohorts and patient allocation to these cohorts will be via slot allocation. Each cohort has a minimum of 3 and a maximum of 6 patients for a total of 21 - 42 patients. The patient population of the dose escalation phase will include patients with advanced NSCLC harboring EGFR classical mutations or Ex20ins mutations, or uncommon mutations. Part 2 includes an expansion phase and the expansion phase will explore one or more dose levels of PLB1004 in NSCLC patients with EGFR Ex20ins mutations, classical mutations, or uncommon mutations.

03

Conditions studied

  • Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to understand and willingness to sign a written document;
  2. Male or female adult patients 18 years of age or older;
  3. Patients should have recovered from toxicities related to prior anti-tumor therapy;
  4. Patients should have recovered from the effects of major surgery;
  5. Have a documented EGFR mutation by a local test in tissue or plasma;
  6. At least 12 weeks ;
  7. Must have at least one per v 1.1;
  8. Sexually active males and females of must agree to take effective measures.

Exclusion criteria

Exclusion Criteria:

  1. Received radiotherapy within 14 days before enrollment;
  2. Have significant or uncontrolled systemic disease;
  3. Have significant or uncontrolled cardiovascular disease;
  4. Have had other diagnosed malignant diseases that required treatment within the past 3 years besides NSCLC;
  5. Currently have or had a history of interstitial lung disease, drug-induced interstitial lung disease, or radiation pneumonia that requires therapy;
  6. Have known to the similar drugs and of PLB1004;
  7. Pregnant or lactating women;
  8. Have used other experimental drugs within 2 weeks prior to the first dose of PLB1004;
  9. Have any condition or illness that could affect the compliance with the protocol.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
81 participants (estimated)

Study arms

  • Experimental
    PLB1004

    PLB1004 given as a mono-therapy in dose escalation and dose expansion phase.

    Drug: PLB1004

Interventions

  • PLB1004 will be orally self-administered by the patient as a mono-therapy.

06

What researchers measure

Primary outcomes

  1. Safety profile of PLB1004 per CTCAE v5.0

    Time frame: Up to 2 years

Secondary outcomes

  1. To define the DLTs and MTD

    Time frame: Up to 3 years

  2. Area Under the Curve (AUC) of PLB1004

    Time frame: Approximately 28 days.

  3. Maximum plasma concentration (Cmax) of PLB1004

    Time frame: Approximately 28 days.

  4. Time to maximum plasma concentration (Tmax) of PLB1004

    Time frame: Approximately 28 days.

  5. Overall Response Rate (ORR)

    Time frame: Up to 3 years

  6. Progression-Free Survival (PFS)

    Time frame: Up to 3 years

  7. Overall Survival (OS)

    Time frame: Up to 3 years

  8. Disease Control Rate (DCR)

    Time frame: Up to 3 years

  9. Duration of Response (DOR)

    Time frame: Up to 3 years

  10. Change from baseline in corrected QT interval (QTc) using Fridericia formula (QTcF)

    Time frame: Up to 3 years

07

Study locations

7 of 7 sites recruiting
  • University of California-Davis
    Sacramento, California 95817-1514, United States
    Recruiting
    • Study Director, MD · Contact
  • Research Site
    Louisville, Kentucky 40202, United States
    Recruiting
  • Nebraska Cancer Specialists
    Omaha, Nebraska 68130, United States
    Recruiting
    • Study Director, MD · Contact
  • Research Site
    New York City, New York 100021, United States
    Recruiting
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
    Recruiting
    • Study Director, MD · Contact
  • Swedish Health Sciences
    Seattle, Washington 98122, United States
    Recruiting
    • Study Director, MD · Contact
  • Research Site
    Seattle, Washington 98195, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Feb 2028, 43 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 43 months is below that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2023
First posted
Sep 21, 2023
StartActual
Jul 8, 2024
Primary completionEst.
Feb 9, 2028
CompletionEst.
Feb 9, 2028
Last update
Apr 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06046495
Lead sponsor
Avistone Biotechnology Co., Ltd.
Responsible party
Sponsor
First posted
Sep 21, 2023
Start date
Jul 8, 2024
Primary completion
Feb 9, 2028 (estimated)
Completion
Feb 9, 2028 (estimated)
Last update
Apr 23, 2025

Study contacts

Avistone Clinical Study Information Center Center
Contact
information.center@avistonebio.com
+86-10-84148921

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Andamertinib

Start the discussion